Literature DB >> 1540414

Antiviral action of polyadenylic-polyuridylic acid against HIV in cell cultures.

A G Laurent-Crawford1, B Krust, E Deschamps de Paillette, L Montagnier, A G Hovanessian.   

Abstract

Polyadenylic-polyuridylic acid referred to as poly(A).poly(U) is a synthetic double-stranded RNA which has been shown to manifest both antitumoral and immunomodulatory activities. Here we used this agent to demonstrate its antiviral activity against the human immunodeficiency virus (HIV-1 and HIV-2). Treatment of cells with poly(A).poly(U) resulted in a significant delay in the development of the HIV-specific cytopathic effect characterized by the formation of syncytia and cell lysis. Furthermore, the production of virus measured by the concentration of the HIV major core protein was reduced by 90-95%. Under these experimental conditions, the synthesis of HIV proteins was reduced at least tenfold whereas the metabolism and proliferation of cells apparently were not affected. The inhibitory action of poly(A).poly(U) seems to be at the level of viral entry into cells. Combined treatment of infected cells with poly(A).poly(U) and azidothymidine (AZT) resulted in a 4-5-fold synergistic inhibitory effect. Previously, no toxicity has been observed in cancer patients with long-term treatment with poly(A).poly(U). In view of this and the significant anti-HIV effect, poly(A).poly(U) provides a potential candidate as a therapeutic drug in AIDS disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540414     DOI: 10.1089/aid.1992.8.285

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection.

Authors:  K A Thompson; D R Strayer; P D Salvato; C E Thompson; N Klimas; A Molavi; A K Hamill; Z Zheng; D Ventura; W A Carter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.